The Hindu Business Line : Ranbaxy gets USFDA nod for overactive bladder drug

RANBAXY Laboratories Ltd has received tentative approval from the US Food and Drug Administration to manufacture and market tolterodine tartrate tablets on 1 and 2 mg dosages.

Tolterodine tartrate tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. The total annual market sale of the product is $98 million and is being marketed under the Detrol brand by Pharmacia.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
BPL to retain alkaline battery business

Ranbaxy gets USFDA nod for overactive bladder drug

L&T wins ONGC rig restoration project

Danlaw Tech pref offer

If RIL backtracks on pact with NTPC, Govt may review KG Basin pact

Eveready acquires BPL battery biz
Deal worth Rs 67 cr; market share to go up to 56 pc

Mercedes steps on biodiesel

Natco Pharma to invest Rs 50 cr in expansion

Wage pact in Tata Steel

Beeyu forms joint venture with Fern Tea for Sri Lanka foray

Novo Nordisk, Aurigene in drug discovery pact

`Indian firms must compete with MNCs in global market'

The growing interest

Exit scheme for defunct cos evokes good response
More firms make use of the scheme's extension till August

Tata Tea chief hints at change in business profile

UB charts Rs 100-cr expansion plan — Announces 15 pc interim dividend